Back to School: How biopharma can reboot drug development. Access exclusive analysis here

APC8024: Phase I

Data from 16 patients in an ongoing Phase I study showed 1 partial response

Read the full 145 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE